Watch APGE. Know when insiders buy.
One email the day a filing lands. Free.
APGE
Apogee Therapeutics, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$294.4MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$96M | −$85.9M | — | -1.14 | −$71.4M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$82.8M | −$74.1M | — | -1.06 | −$55.6M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$78.1M | −$69.4M | — | -1.03 | −$62.7M | $62K | −$62.8M | Mar 2 |
| Q3 2025 · Sep 30 | — | — | — | −$71.3M | −$65M | — | -1.11 | −$54.3M | $0 | −$54.3M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$73.2M | −$66.1M | — | -1.13 | −$62M | $768K | −$62.8M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$63.1M | −$55.3M | — | -0.95 | −$48.5M | $4.3M | −$52.8M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$75.9M | −$67.2M | — | -1.19 | −$67.7M | −$1K | −$67.7M | Mar 2 |
| Q3 2024 · Sep 30 | — | — | — | −$58.7M | −$49M | — | -0.86 | −$42.5M | $751K | −$43.3M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$44.1M | −$33.8M | — | -0.60 | −$29.3M | $51K | −$29.4M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$38.2M | −$32.1M | — | -0.64 | −$31.6M | $351K | −$32M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$37.2M | −$31.7M | — | -0.32 | −$29.8M | — | — | Mar 2 |
| Q3 2023 · Sep 30 | — | — | — | −$24.3M | −$20.8M | — | -0.51 | −$19.9M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$285.6M | −$255.8M | — | -4.22 | −$227.4M | $5.1M | −$232.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$216.9M | −$182.1M | — | -3.30 | −$171.2M | $1.2M | −$172.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$93M | −$84M | — | -3.36 | −$74.8M | $167K | −$74.9M | — | — |
Every number comes from Apogee Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.